Twentyeight-Seven Therapeutics
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Twentyeight-Seven Therapeutics firmographics
Firmographics- Name
- Twentyeight-Seven Therapeutics
- Website
- https://twentyeight-seven.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Twentyeight-Seven Therapeutics industry classification
Industry- Product category
- MicroRNA Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
- akta.pro secondary industries
- siRNA Therapeutics (gene silencing) (HLAAADAB), RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
Keywords
Where Twentyeight-Seven Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Markets served
Twentyeight-Seven Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Twentyeight-Seven Therapeutics product offering
Product offeringCore offering
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins, with a focus on therapeutic applications in oncology. The company leverages RNA biology to develop drug candidates that modulate expression of specific proteins implicated in disease.
Differentiator
Problem solved
Functional benefit
Products and services
- MicroRNA therapeutic candidates
Companies that use Twentyeight-Seven Therapeutics
Customer profileIdeal customer profiles1 record
Twentyeight-Seven Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Twentyeight-Seven Therapeutics partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights4 records
Twentyeight-Seven Therapeutics competitors and assessment
Company assessmentDirect peers
- miRagen Therapeutics (now Viridian Therapeutics): Originally focused on microRNA therapeutics for hematological and cardiovascular indications. Direct miRNA modality peer whose clinical experience provides relevant industry benchmarks.
- Regulus Therapeutics: Clinical-stage biotech developing microRNA-targeted therapeutics for kidney disease and other indications. Most directly comparable peer given shared microRNA therapeutic modality.
Emerging players
- Wave Life Sciences: Clinical-stage company developing stereopure oligonucleotide therapeutics. Comparable nucleic acid platform with differentiated chemistry approach.
- ProQR Therapeutics: RNA editing-based therapeutics company focused on genetic diseases. Comparable as an emerging RNA-targeted therapeutic platform addressing gene expression.
Broad incumbents
- Alnylam Pharmaceuticals: Leading commercial-stage siRNA therapeutics company with approved products. Sets the competitive benchmark for RNA-targeted therapeutics and validates the broader RNA therapeutic commercial thesis.
- Ionis Pharmaceuticals: Antisense oligonucleotide (ASO) therapeutics leader with broad pipeline. Comparable as a nucleic acid therapeutics platform targeting regulatory proteins.
- Dicerna Pharmaceuticals (Novo Nordisk): siRNA therapeutics company acquired by Novo Nordisk. Direct RNA-targeting competitor that validates the therapeutic modality and represents a potential acquirer profile.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with multiple programs across liver, lung, and CNS indications. Comparable in modality and development stage approach.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks4 records
Key highlights5 records
Customer concentration
Twentyeight-Seven Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Twentyeight-Seven Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Twentyeight-Seven Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Twentyeight-Seven Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Twentyeight-Seven Therapeutics
What does Twentyeight-Seven Therapeutics do?
Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins, with a focus on therapeutic applications in oncology. The company leverages RNA biology to develop drug candidates that modulate expression of specific proteins implicated in disease.
Is Twentyeight-Seven Therapeutics a public or private company?
Twentyeight-Seven Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Twentyeight-Seven Therapeutics founded?
Twentyeight-Seven Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Twentyeight-Seven Therapeutics based?
Twentyeight-Seven Therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are Twentyeight-Seven Therapeutics's main competitors?
Direct peers on record are miRagen Therapeutics (now Viridian Therapeutics) and Regulus Therapeutics. Emerging players are Wave Life Sciences and ProQR Therapeutics. Broad incumbents are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Dicerna Pharmaceuticals (Novo Nordisk) and Arrowhead Pharmaceuticals.
Does Twentyeight-Seven Therapeutics have an API?
No public API is recorded for Twentyeight-Seven Therapeutics.
What industry is Twentyeight-Seven Therapeutics in?
Twentyeight-Seven Therapeutics's product category is MicroRNA Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAADAB, siRNA Therapeutics (gene silencing). Its NAICS code is 541714 and its SIC code is 2834.